BNP Paribas Asset Management
KERX

BNP Paribas Asset Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

BNP Paribas Asset Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-292,478
Closed -$3.72M – 1098
2015
Q1 		$3.72M Buy
292,478
+66,226
+29% +$851K 0.03% 560
2014
Q4 		$3.2M Sell
226,252
-22,734
-9% -$352K 0.03% 522
2014
Q3 		$3.42M Buy
+248,986
New +$3.81M 0.03% 511

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return

BNP Paribas Asset Management's KERX Position: Q2 2015 in Review

BNP Paribas Asset Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q2 2015, closing a stake of 292,478 shares — an estimated $3.72M sold.

BNP Paribas Asset Management first reported a position in KERX in Q3 2014 and held it in 3 quarters. The position peaked at $3.72M in Q1 2015. 153 funds tracked by Wall St. Rank hold KERX as of Q2 2015.

  • BNP Paribas Asset Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q2 2015 after selling out during the quarter.
  • BNP Paribas Asset Management sold 292,478 Keryx Biopharmaceuticals Inc shares in Q2 2015, an estimated $3.72M.
  • BNP Paribas Asset Management first reported a position in Keryx Biopharmaceuticals Inc in Q3 2014 and held it in 3 quarters.
  • BNP Paribas Asset Management's Keryx Biopharmaceuticals Inc position peaked at $3.72M in Q1 2015.
  • 153 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2015.

Based on BNP Paribas Asset Management's 13F filing for Q2 2015, filed 14 Aug 2015.